Joseph M Kim1, Jacob A Miller2, Rupesh Kotecha3, Samuel T Chao4,5,6, Manmeet S Ahluwalia4,6,7, David M Peereboom4,6,7, Alireza M Mohammadi4,6,8, Gene H Barnett4,6,8, Erin S Murphy4,5,6, Michael A Vogelbaum4,6,8, Lilyana Angelov4,6,8, Jame Abraham4,7, Halle Moore4,7, G Thomas Budd4,7, John H Suh4,5,6. 1. School of Medicine, Case Western Reserve University, Cleveland Clinic, Cleveland, Ohio. 2. Department of Radiation Oncology, Stanford Cancer Institute, Stanford University Medical Center, Palo Alto, California. 3. Department of Radiation Oncology, Miami Cancer Institute, Miami, Florida. 4. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio. 5. Department of Radiation Oncology, Taussig Cancer Institute, Cleveland, Ohio. 6. Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Taussig Cancer Institute, Cleveland, Ohio. 7. Department of Medical Oncology, Taussig Cancer Institute, Cleveland, Ohio. 8. Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
Abstract
BACKGROUND: Patients with breast cancer positive for human epidermal growth factor receptor 2 (HER2) remain at high risk of intracranial relapse following treatment and experience increased rates of intracranial failure after stereotactic radiosurgery (SRS). We hypothesized that the addition of concurrent lapatinib to SRS would improve intracranial complete response rates. METHODS: Patients with newly diagnosed HER2-amplified breast cancer brain metastases from 2005-2014 who underwent SRS were included and divided into 2 cohorts based on timing of treatment with lapatinib. Outcome variables included the proportion of patients who achieved an intracranial complete response or progressive disease according to the RECIST 1.1 criteria, as well as individual lesion response rates, distant intracranial failure, and radiation necrosis. RESULTS: Eighty-four patients with 487 brain metastases met inclusion criteria during the study period. Over 138 treatment sessions, 132 lesions (27%) were treated with SRS and concurrent lapatinib, while 355 (73%) were treated with SRS without lapatinib. Compared with patients treated with SRS alone, patients treated with concurrent lapatinib had higher rates of complete response (35% vs 11%, P = 0.008). On a per-lesion basis, best objective response was superior in the concurrent lapatinib group (median 100% vs 70% reduction, P < 0.001). Concurrent lapatinib was not associated with an increased risk of grade 2+ radiation necrosis (1.0% with concurrent lapatinib vs 3.5% without, P = 0.27). Lapatinib had no protective effect on distant intracranial failure rates (48% vs 49%, P = 0.91). CONCLUSION: The addition of concurrent lapatinib to SRS was associated with improved complete response rates among patients with HER2-positive brain metastases.
BACKGROUND:Patients with breast cancer positive for human epidermal growth factor receptor 2 (HER2) remain at high risk of intracranial relapse following treatment and experience increased rates of intracranial failure after stereotactic radiosurgery (SRS). We hypothesized that the addition of concurrent lapatinib to SRS would improve intracranial complete response rates. METHODS:Patients with newly diagnosed HER2-amplified breast cancer brain metastases from 2005-2014 who underwent SRS were included and divided into 2 cohorts based on timing of treatment with lapatinib. Outcome variables included the proportion of patients who achieved an intracranial complete response or progressive disease according to the RECIST 1.1 criteria, as well as individual lesion response rates, distant intracranial failure, and radiation necrosis. RESULTS: Eighty-four patients with 487 brain metastases met inclusion criteria during the study period. Over 138 treatment sessions, 132 lesions (27%) were treated with SRS and concurrent lapatinib, while 355 (73%) were treated with SRS without lapatinib. Compared with patients treated with SRS alone, patients treated with concurrent lapatinib had higher rates of complete response (35% vs 11%, P = 0.008). On a per-lesion basis, best objective response was superior in the concurrent lapatinib group (median 100% vs 70% reduction, P < 0.001). Concurrent lapatinib was not associated with an increased risk of grade 2+ radiation necrosis (1.0% with concurrent lapatinib vs 3.5% without, P = 0.27). Lapatinib had no protective effect on distant intracranial failure rates (48% vs 49%, P = 0.91). CONCLUSION: The addition of concurrent lapatinib to SRS was associated with improved complete response rates among patients with HER2-positive brain metastases.
Authors: E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: Brunilde Gril; Diane Palmieri; Julie L Bronder; Jeanne M Herring; Eleazar Vega-Valle; Lionel Feigenbaum; David J Liewehr; Seth M Steinberg; Maria J Merino; Stephen D Rubin; Patricia S Steeg Journal: J Natl Cancer Inst Date: 2008-07-29 Impact factor: 13.506
Authors: Johanna C Bendell; Susan M Domchek; Harold J Burstein; Lyndsay Harris; Jerry Younger; Irene Kuter; Craig Bunnell; Montse Rue; Rebecca Gelman; Eric Winer Journal: Cancer Date: 2003-06-15 Impact factor: 6.860
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Nancy U Lin; Véronique Diéras; Devchand Paul; Dominique Lossignol; Christos Christodoulou; Hans-Joachim Stemmler; Henri Roché; Minetta C Liu; Richard Greil; Eva Ciruelos; Sibylle Loibl; Stefania Gori; Andrew Wardley; Denise Yardley; Adam Brufsky; Joanne L Blum; Stephen D Rubin; Bernie Dharan; Klaudia Steplewski; Denise Zembryki; Cristina Oliva; Debasish Roychowdhury; Paolo Paoletti; Eric P Winer Journal: Clin Cancer Res Date: 2009-02-15 Impact factor: 12.531
Authors: Pierre-Yves Borius; Jean Régis; Alexandre Carpentier; Michel Kalamarides; Charles Ambroise Valery; Igor Latorzeff Journal: Cancer Metastasis Rev Date: 2021-01-04 Impact factor: 9.264
Authors: Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300
Authors: Jing Li; Jun Jiang; Xun Bao; Vineet Kumar; Stephen C Alley; Scott Peterson; Anthony J Lee Journal: Clin Cancer Res Date: 2022-08-02 Impact factor: 13.801
Authors: Matthew N Mills; Chetna Thawani; Nicholas B Figura; Daniel E Oliver; Aixa E Soyano; Arnold Etame; Timothy J Robinson; James K Liu; Michael A Vogelbaum; Peter A Forsyth; Brian J Czerniecki; Hatem H Soliman; Hyo S Han; Hsiang-Hsuan Michael Yu; Kamran A Ahmed Journal: J Neurooncol Date: 2021-03-19 Impact factor: 4.130